Key facts
- Hormona’s last known valuation is $20.3M (May 2025).
- It has raised $12.3M; the latest was Later Stage VC ($10.4M) in May 2025.
- Notable investors include Techstars, SFC Capital, DLF Venture, Advenimus AB, Blackheath Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Hormona
- ·The full record, as it builds
Funding rounds
No funding rounds for Hormona are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hormona
Developer of a femtech-based platform designed to improve female health and well-being. The company's technology allows women to take control of their health through daily measurement, tracking, and insights that optimize their well-being, enabling users to track their hormones and confidently manage their lives.
- Sector
- Consumer Products and Services (B2C)
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 12
- Website
- hormona.io/
- Ownership
- Privately Held (backing)
Hormona doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hormona shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hormona in its N-PORT filings yet. We sweep new filings monthly.